# Clinical Trials Data KRAS - Document 25

# A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors

## Clinical Trial: https://clinicaltrials.gov/study/NCT01449058

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Histologically/cytologically confirmed, advanced solid tumors, AML or high risk and very high risk MDS\n\* Measurable disease as determined by RECIST 1.1\n\nExclusion Criteria:\n\n\* Primary CNS tumor or CNS tumor involvement\n\* Diabetes mellitus\n\* Unacceptable ocular/retinal conditions\n\* Clinically significant cardiac disease or impaired cardiac function",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a KRAS gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided clinical trial information, there are no criteria related to KRAS gene mutations mentioned in either the inclusion or exclusion criteria. Therefore, a patient with a KRAS gene mutation would be eligible for the clinical trial as long as they meet the other eligibility requirements (such as having a confirmed advanced solid tumor, AML, or high-risk MDS, measurable disease, and not having any exclusion conditions like primary CNS tumor, diabetes mellitus, unacceptable ocular/retinal conditions, or significant cardiac disease).